WO1999019303A1 - Derives de pyrazole - Google Patents
Derives de pyrazole Download PDFInfo
- Publication number
- WO1999019303A1 WO1999019303A1 PCT/JP1998/004583 JP9804583W WO9919303A1 WO 1999019303 A1 WO1999019303 A1 WO 1999019303A1 JP 9804583 W JP9804583 W JP 9804583W WO 9919303 A1 WO9919303 A1 WO 9919303A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- substituents
- pyrazole
- optionally
- trifluoromethyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Definitions
- the present invention relates to a medicament, particularly a pyrazole derivative having a calcium release-dependent calcium channel inhibitory action, and a pharmaceutical composition containing the same as an active ingredient, particularly a calcium release-dependent calcium channel inhibitor.
- V ⁇ CC membrane potential-dependent Ca 2+ channel
- C a 2+ influx mechanisms i.e. calcium release-dependent calcium channels from selective extracellularly C a 2 + that caused attract by C a 2 + Store ⁇ ( Ca 2 + release activated Ca 2 + channel; hereafter abbreviated as CRAC C; presence of calcium store-dependent calcium channel (store-dependent Ca 2+ channel); and mast cell / lymphocyte membrane It has been reported that it is insensitive to potential (Pflugers Arch., 430, p315-22 (1995)). CRACC is known to be present in almost all inflammatory cells, such as mast cells, lymphocytes, and astrocytes (J. Biol. Chem., 270, ⁇ 29-32 (1995)).
- CRACC inhibitory activity Ce 11 Calcium 14, pl-16 (1993)
- CRACC inhibitors may show clinical utility in chronic inflammatory diseases such as rheumatoid arthritis.
- CRACC may also be present on endothelial cells (Am. J. Physiol., 269, C733-8 (1995)) and epithelial cells (J. Biol. Chem., 270, ⁇ 169-75 (1995)).
- endothelial cells Am. J. Physiol., 269, C733-8 (1995)
- epithelial cells J. Biol. Chem., 270, ⁇ 169-75 (1995)
- CRAC C inhibitors are useful as prophylactic / therapeutic agents for proliferative or progressive diseases such as malignant tumors, and autoimmune diseases, and as inhibitors of rejection during transplantation. .
- excitable cells typified by smooth muscle cells and nerve cells are known to regulate intracellular calcium by VOCC and do not involve CRACC. Therefore, calcium channel inhibitors that have CRACC selectivity for VOCC have no adverse effects on vascular smooth muscle and central nervous system, and are suitable for various inflammatory diseases, allergic diseases, autoimmune diseases, tissue damage, and proliferation. It is expected to be a useful drug for prevention or treatment of sexual diseases.
- German Offenlegungsschrift 2525024 discloses 5- (heterocycloylaminophenyl) -111-phenylpyrazole derivatives exhibiting anti-inflammatory activity.
- German Offenlegungsschrift 2525024 discloses 5- (heterocycloylaminophenyl) -111-phenylpyrazole derivatives exhibiting anti-inflammatory activity.
- a CRACC inhibitory action or an IL-12 production inhibitory action there is no disclosure or suggestion of a CRACC inhibitory action or an IL-12 production inhibitory action.
- W095 / 18097 discloses an anthranilic acid derivative represented by the following formula and having a cyclic GMP phosphodiesterase inhibitory action.
- R 4 is, H, halogen atom, ⁇ ⁇ ⁇ , pyrazolyl but it may also be substituted, ...; n is 0 to 6, W is N or CH, Y is 0 or
- JP-A-9-159236 discloses an R 1 , R 2 -disubstituted benzamide derivative represented by the following formula, which is useful for the prevention and treatment of rheumatic, allergic and other inflammatory diseases.
- R 1 is a substituted or unsubstituted aromatic heterocyclic group
- ⁇ R 2 is a halogen atom, a nitro group, — NR 5 R 6 , ⁇
- R 3 and R 3 each represent a substituted or unsubstituted aromatic hydrocarbon group or a substituted or unsubstituted aromatic heterocyclic group. See).
- pyrazolyl as the aromatic heterocyclic group for R 1 .
- a CRACC inhibitory action or an IL-12 production inhibitory action there is no disclosure of a CRACC inhibitory action or an IL-12 production inhibitory action.
- the present inventors have diligently searched for compounds having an excellent CRACC inhibitory action. As a result, they have found that a pyrazole derivative having a completely different structure from a compound which has been reported to have a CRACC inhibitory action has an excellent CRACC inhibitory action. Furthermore, they have found that these compounds have high CRACC selectivity for VOCC, and have completed the present invention.
- the present invention relates to a novel pyrazole derivative characterized by having a pyrazolyl group represented by the following general formula (I) or a pharmaceutically acceptable salt thereof.
- a novel pyrazole derivative characterized by having a pyrazolyl group represented by the following general formula (I) or a pharmaceutically acceptable salt thereof.
- lower alkyl is abbreviated as A 1 k
- halogen atom is abbreviated as Ha 1.
- D —A lk, one lower alkenyl, —lower alkynyl, —halogeno lower alkyl, —A 1k—cycloalkyl, —A lk— ⁇ —A lk, one cycloalkyl, —0_A lk, one C ⁇ H, Pyrazolyl optionally having 1 to 3 substituents selected from the group consisting of one C ⁇ —A 1 k and —Ha 1, n: 0 or 1,
- B phenylene, a divalent group of a nitrogen-containing saturated ring or a divalent group of a monocyclic aromatic hetero ring which may be substituted with A 1 k,
- R 1 — H, -OH, —A lk, one O—A 1 k or _C ⁇ one A 1 k,
- R 4 , R 5 same or different, 1 H, -Ha—halogeno lower alkyl or 1 A 1 k,
- A a benzene ring which may have one or more substituents; a monocyclic or bicyclic to tricyclic fused heteroaryl which may have one or more substituents; one or more substituents Optionally having a cycloalkyl group; having one or more substituent groups An optionally substituted nitrogen-containing saturated ring; a lower alkenyl optionally having one or more substituents; a lower alkynyl optionally having one or more substituents; or one or more substituents.
- a 1 k which may have
- A is integral with X and the expression
- a 2 is a nitrogen-containing compound selected from the group consisting of 1-pyrrolidinyl, birazolidinyl, piperidino, piperazinyl, morpholino, 3,4-dihydro-2H-1,4-benzoxazine-4-yl, and indlinyl
- the heterocyclic ring may have one or more substituents.
- D is 1H—pyrazol — 1—yl, n is 0, B is 1,4-phenylene
- the present invention provides a pharmaceutical composition comprising a pyrazole derivative represented by the following general formula (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier,
- the present invention relates to a pharmaceutical composition for inhibiting a calcium channel.
- the present invention relates to an IL-2 production inhibitor, an agent for preventing or treating allergic, inflammatory or autoimmune diseases, and an agent for preventing or treating bronchial asthma or rheumatoid arthritis.
- D —A 1 k, one lower alkenyl, one lower alkynyl, —halogeno lower alkyl, one A 1 k—cycloalkyl, — A lk— 0—A lk, —cycloalkyl, —O—A lk, — CO ⁇ Pyrazolyl optionally having 1 to 3 substituents selected from the group consisting of H, —COO—A 1 k and —H a1, n: 0 or 1
- B phenylene, a divalent group of a nitrogen-containing saturated ring or a divalent group of a monocyclic aromatic hetero ring which may be substituted with A 1 k,
- R ' — H, -OH, — Alk, — 0_A 1 k or — CO— A 1 k,
- R 4 , R 5 same or different, —H, —Ha—halogeno lower alkyl or _A 1 k,
- A a benzene ring which may have one or more substituents; a monocyclic or bicyclic to tricyclic fused heteroaryl which may have one or more substituents; one or more substituents A nitrogen-containing saturated ring optionally having one or more substituents; a lower alkenyl optionally having one or more substituents; one or more substituents Lower alkynyl optionally having a group; or 1 A 1 k optionally having at least two substituents,
- A is integral with X and the expression
- a 2 is selected from the group consisting of 1-pyrrolidinyl, pyrazolidinyl, piperidino, piperazinyl, morpholino, 3,4-dihydro-2H-1,4_benzoxazine-14yl, and indolinyl A heterocyclic ring, which may have one or more substituents.
- a 2 is selected from the group consisting of 1-pyrrolidinyl, pyrazolidinyl, piperidino, piperazinyl, morpholino, 3,4-dihydro-2H-1,4_benzoxazine-14yl, and indolinyl A heterocyclic ring, which may have one or more substituents.
- the general formula ( ⁇ ) includes the following known compounds.
- Compounds A to D are listed in SEY04225, KM 02940, MAYBR IDGE's reagent catalog (UK, Cornwa 11; published in August 1995). It is described as KMO 3000 and GKO 2421, but its use has not been reported at all, not only for pharmaceutical use but also for other uses.
- Compound E is disclosed in JP-A-61-82 as a raw material for the production of pharmaceuticals, but there is no description of its pharmacological action. Therefore, pharmaceutical compositions containing these known compounds are novel.
- Preferable compounds of the general formula (I) or ( ⁇ ) of the present invention include pyrazolyl in which the pyrazolyl group of D is substituted by at least one trifluoromethyl group, especially 1H-virazol-1-yl. Or a pyrazole derivative which is 1H-pyrazol-1-yl or a pharmaceutically acceptable salt thereof.
- phenyl wherein A may have one or more substituents of group F; monocyclic or bicyclic or tricyclic fused heteroaryl which may have one or more substituents of group F
- a cycloalkyl optionally having one or more substituents of group F; a nitrogen-containing saturated ring optionally having one or more substituents of group F; one or more substituents of group G
- a lower alkenyl which may have one or more substituents of group G
- an alk which may have one or more substituents of group G.
- Group F includes — A lk, lower alkenyl, lower alkynyl, — Ha l, one NH 2 , —NH (A 1 k), — N (A 1 k) 2 , — N0 2 , — CN, -OH , _ ⁇ ⁇ A lk, — O— CO— A lk, — SH, _S_A lk, one COO H, one COO-A lk, one CO-A lk, one CHO, one CONH 2 , one CONH (A 1 k), -CON (A 1 k) 2 , one SO—A lk, _S ⁇ 2 _A lk, — S ⁇ 2 NH 2 , —S0 2 NH— (A 1 k), — S0 2 N (A 1 k) 2 , —aryl, —cycloalkyl, — ⁇ A lk— ⁇ one, —halogeno lower alkyl, one
- Group G is _Ha l, — NH 2 , one NH (A lk), — N (A lk) 2 , — N 0 2 , one CN, -OH, one hundred one A lk, one O — CO — A lk : one SH, one S- A lk, _COOH, one COO- A lk one CO- A lk, _C HO, one CONH 2, - CONH (A lk ), -CON (A lk) 2, _SO- A lk, one S0 2 — A lk: one S ⁇ 2 NH 2 , — S ⁇ 2 NH-(A lk), — S0 2 N (A 1 k) 2 , having one or more substituents of group F
- a monocyclic or bicyclic to tricyclic fused heteroaryl which may have one or more F group substituents, and one or more F group substituents And a nitrogen-containing saturated
- A is integral with X and the expression
- a 2 is selected from the group consisting of 1-pyrrolidinyl, virazolidinyl, piperidino, piperazinyl, morpholino, 3,4-dihydro-1H- 1,4-benzobenzoxazine-4-yl, and indolinyl Wherein the heterocyclic ring may have one or more substituents of group F.
- B is phenylene; piperidine-1,4-diyl; or A 1 k, optionally substituted with thiophene, furan, pyrrolyl, imidazole, pyrazole, thiazole, isothiazoyl.
- a monocyclic aromatic heterocyclic divalent group selected from the group consisting of benzoyl, oxazolyl, isoxazolyl, thiadiazol, pyridine, pyrazine, pyridazine and pyrimidine, and X is one NH — CO—, _NH— CH 2 —, — N (OH) _C ⁇ _ — N (A 1 k) -CO-, — CO— NH—, — CH 2 — NH —, —CO -N (OH) one, one CO— N (A 1 k) —, one S ⁇ 2 NH- , —NHS ⁇ 2 — or — CH C (Ha l) —, and A is an aryl which may have one or more group F substituents; one or more group F substituents , Thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, thiazolyl, isothiazolyl
- A is integral with X and the expression
- D is —A lk, —halogeno lower alkyl, —COOH and —COO-A 1-pyrazolyl optionally having 1 to 3 substituents selected from the group consisting of 1 k
- B is a monovalent aromatic heterocyclic divalent group selected from the group consisting of thiophene, furan, thiazol, pyridine and pyrimidine, which may be substituted with phenylene or A 1 k.
- X is _NH-CO-, one N (OH) -CO-, —CO—NH—, one CH 2 _NH— or one C ⁇ —N (A 1 k) —, and A is one A lk, -Ha — NH 2 , -N (A 1 k) 2 , —N0 2 , one CN, -OH, — ⁇ —A 1 k and — COO-A 1 k Phenyl optionally having the above substituents; A1k optionally substituted with phenyl, pyrrolyl, imidazolyl, thiazolyl, oxazolyl, tetrazolyl, triazolyl, thiadiazolyl, A monocyclic or 2- to 3-cyclic fused heteroaryl selected from the group consisting of pyridyl, virazinyl and isoquinolyl; cycloalkyl; lower alkenyl optionally substituted by one or more Ha 1, or A 1 k
- X is — NH—CO— or —CO—NH—
- D is 1-methyl-3-trifluoromethyl-1H-virazol-5-yl
- A is phenyl optionally substituted with Ha 1
- D is 3,5- A monocyclic ring selected from the group consisting of thiazolyl, thiadiazolyl, chenyl and pyridyl, which is bis (trifluoromethyl) -1H-pyrazol-1-yl, and A may be substituted with A 1 k Heteroaryl, a pyrazole derivative or a pharmaceutically acceptable salt thereof.
- lower means a straight or branched carbon chain having 1 to 6 carbon atoms, unless otherwise specified.
- Preferred examples of the “lower alkyl (A 1 k)” include methyl, ethyl, and propyl, and examples of the “lower alkenyl” include vinyl, 1-probenyl, and 1,2-dimethyl-1-propenyl.
- lower alkynyl include ethynyl.
- Halogen atom (Ha l) I, Br, F and CI.
- the “halogeno lower alkyl” is A 1k substituted with one or more H a1, and particularly preferably trifluoromethyl.
- Aryl is an aryl group having 6 to 14 carbon atoms, preferably phenyl and naphthyl.
- Cycloalkyl is cycloalkyl having 3 to 8 carbon atoms, preferably cyclopropyl and cyclohexyl.
- Divalent group of monocyclic aromatic heterocycle means a divalent group of a 5- to 6-membered monocyclic aromatic heterocycle containing 1 to 4 heteroatoms selected from N, S and O atoms. Particularly preferred are furan-2,5-diyl, thiophen-1,2,5-diyl, thiazolu-2,5-diyl, pyridine-2,5-diyl and pyrimidine-2,5-diyl.
- the “phenylene” is preferably 1,4-phenylene.
- the term "monocyclic or bicyclic to tricyclic fused heteroaryl” refers to a 5- to 6-membered monocyclic or bicyclic to tricyclic fused ring containing 1 to 5 ⁇ , S or N atoms as hetero atoms. It is a ring.
- the “nitrogen-containing saturated ring” is a 5- to 6-membered nitrogen-containing saturated heterocyclic ring containing 1 to 2 N atoms as ring atoms and optionally containing 0 or 1 S atom.
- the “divalent group of a nitrogen-containing saturated ring” is preferably piperidine-1,4-diyl. When n is 0, D and B are directly connected.
- a geometric isomer or a tautomer may exist, but the present invention includes a separated form or a mixture of these isomers. Further, the compound of the present invention may have an asymmetric carbon atom, and the (R) -form and the (S) -form optical isomer based on this may exist.
- the present invention embraces mixtures and isolated forms of these optical isomers.
- the compound (I) or (II) of the present invention may form a salt with an acid addition salt or a salt depending on the type of the substituent.
- a salt is a pharmaceutically acceptable salt, preferably an inorganic acid such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, etc., formic acid, acetic acid, propionic acid, and sulfur.
- examples thereof include salts with inorganic bases such as aluminum, potassium, magnesium, calcium, and aluminum, salts with organic bases such as methylamine, eluamine, ethanolamine, lysine, and ordinine, and ammonium salts.
- the present invention also encompasses various hydrates, solvates, and polymorphs of the compound (I) or (II) of the present invention and salts thereof.
- the compound of the present invention and a pharmaceutically acceptable salt thereof can be produced by applying various known synthetic methods, utilizing characteristics based on the basic skeleton or the types of substituents. At this time, depending on the type of the functional group, it is effective in production technology to replace the functional group with an appropriate protecting group at the stage of the raw material or intermediate, that is, a group that can be easily converted to the functional group. There are cases. Thereafter, the desired compound can be obtained by removing the protecting group, if necessary.
- Examples of such a functional group include a hydroxyl group and a hydroxyl group, and examples of such a protecting group include Darin (Greene) and Wuts (Wuts, Protective Groups in Organic Synthes is),
- the protecting groups described in the second edition can be mentioned, and these may be appropriately used according to the reaction conditions.
- an amine derivative represented by the general formula (II) or (V) and a carboxylic acid derivative represented by the general formula (III) or (IV) are subjected to an amidation reaction.
- Three IV) is a free carboxylic acid or a reactive derivative thereof.
- acid halides such as acid chloride and acid bromide
- acid azide methanol, ethanol, benzyl alcohol, phenol which may be substituted, 1-hydroxybenzotriazole, N-hydroxysuccinimide, etc.
- Active esters symmetric acid anhydrides; mixed acid anhydrides with alkyl carbonic acid, P-toluenesulfonic acid, and the like.
- the amidation reaction can be performed by a conventional method.
- a condensing agent such as ⁇ , ⁇ 'dicyclohexyl carbodiimide (DCC), or 1- (3-dimethylaminopropyl) -3-ethylethyl carbodiimide (WS CD) is used during the reaction.
- carboxylic acids such as 1,1'-carbonyldiimidazole, ⁇ , ⁇ '-disuccinimidyl carbonate, diphenylphosphoryl azide, phosphorus oxychloride, phosphorus trichloride, and triphenylphosphine-bromosuccinimide
- an activator is used.
- the reaction is carried out using an equimolar amount or an excess amount of one of the amine derivative represented by the general formula (II) or (V) and the carboxylic acid derivative represented by the general formula (III) or (IV), and the reaction is inert.
- Organic solvents such as pyridine, tetrahydrofuran (THF), dioxane, ether, benzene, toluene, dichloromethane, 1,2-dichloroethane (DCE), chloroform, ⁇ ⁇ , ⁇ -dimethylformamide (DMF)
- THF tetrahydrofuran
- DCE 1,2-dichloroethane
- DMF 1,2-dichloroethane
- the reaction is carried out in a solvent such as ethyl acetate, acetonitrile and the like.
- the reaction temperature is appropriately selected depending on the type of the reaction inducer.
- a base such as triethylamine, pyridine, picoline, ,, ⁇ -dimethylaniline, potassium carbonate, sodium sulphate, etc.
- a base such as triethylamine, pyridine, picoline, ,, ⁇ -dimethylaniline, potassium carbonate, sodium sulphate, etc.
- Pyridine can also serve as a solvent.
- R a and R b represent H or A 1k.
- the compound of the present invention is obtained by subjecting the carbon atom adjacent to the ketone of the compound represented by the general formula (VI) to trifluoroacetyl iridation, and then reacting with a hydrazine derivative to form a ring. 1-3).
- trifluoroacetylation is carried out in the presence of a base such as sodium methoxide, sodium ethoxide, alkali metal hexamethyldisilazide, alkali metal hydride, alkyllithium, and triethylamine.
- a base such as sodium methoxide, sodium ethoxide, alkali metal hexamethyldisilazide, alkali metal hydride, alkyllithium, and triethylamine.
- reaction can be carried out under heating and reflux from 78 ° C.
- the compound obtained in the first step and the hydrazine derivative are converted into an acid such as acetic acid or hydrochloric acid, or titanium (IV) isopropoxide, titanium (IV) chloride, boron trifluoride dimethyl ether complex or the like.
- the reaction can be carried out in the presence or absence of a Lewis acid in a solvent such as methanol or ethanol, or without a solvent. This reaction can be performed under cooling or heating to reflux.
- both compounds are reacted in the same inert solvent as in the first process amidation, and the resulting Schiff base is isolated or the Schiff base is reduced without isolation.
- the reaction temperature is appropriately set, but is preferably from room temperature to reflux.
- Reduction of Schiff bases is accomplished by adding a metal hydride complex (sodium cyanoporolohydride, sodium triacetoxypollohydride, sodium borohydride, etc.) or a reducing agent such as borane, and heating at 20 ° C under reflux.
- a metal hydride complex sodium cyanoporolohydride, sodium triacetoxypollohydride, sodium borohydride, etc.
- a reducing agent such as borane
- X is - S0 2 - NR 1 - or - NR 1 - S0 2 - the Compound is, instead of the force Lupo phosphate derivatives, except using a sulfonic acid derivative can be produced in the same manner as the first production method Can be.
- olefins can be synthesized by forming olefins by a Wittig) reaction.
- This reaction can be carried out in the presence of a base such as lithium diisopropylamide, sodium hydride, triethylamine, alkyllithium, phenyllithium, etc., in a solvent such as THF, DMF or the like, under heating and reflux from 178.
- a base such as lithium diisopropylamide, sodium hydride, triethylamine, alkyllithium, phenyllithium, etc.
- solvent such as THF, DMF or the like
- N-alkylation of the nitrogen atom of the amino or amide group of X and the N-alkylation of the ring nitrogen atom can be carried out in the usual manner by N-alkylation, for example, with an amine derivative, a) logogen atom or an organic sulfone residue.
- An alkyl compound having a common leaving group such as a group
- a base such as potassium carbonate, triethylamine, sodium hydride, or the like
- an inert solvent such as DMF, acetone, 2-butanone, or acetonitrile, or without a solvent. This can be done by reacting under reflux.
- the starting compounds for the above-mentioned production methods are commercially available or can be easily synthesized by methods known to those skilled in the art.
- the reaction products obtained by each of the above processes are isolated and purified as free compounds, their salts, hydrates or various solvates.
- Salt can be produced by subjecting it to the usual process: Isolation and purification are performed by applying ordinary chemical procedures such as extraction, concentration, distillation, crystallization, filtration, recrystallization, and various types of chromatography.
- Various isomers can be isolated by a conventional method using physical differences between the isomers.
- the optical isomers can be separated by a general racemic resolution method, for example, fractional crystallization or chromatography.
- the optical isomer can also be synthesized from a suitable optically active starting material.
- the compounds of the present invention are useful as active ingredients in pharmaceutical compositions.
- it has a CRACC inhibitory action and an IL-12 production inhibitory action, and is useful as a shakuhachi (inhibitor or 1L-2 production inhibitor).
- the allergic, inflammatory or autoimmune diseases include bronchial asthma, psoriasis, atopic diseases including atopic dermatitis, inflammatory bowel diseases including Crohn's disease, peptic ulcer, nephritis, hepatitis, ⁇ Inflammatory diseases, collagen diseases, rheumatoid arthritis, osteoarthritis, rejection at the time of transplantation, etc., include various diseases involving the production of 3 or 1 L_2.
- the properties are determined by CRACC inhibitory activity and IL (1)
- In vitro test results such as the production inhibitory effect, as well as antigen-induced airway eosinophil infiltration models, which are typical disease models of bronchial asthma, disease models involving T cell activation, and mouse collagen arthritis model This is clear from the results of various tests using animal disease models.
- the compounds of the present invention also have an inhibitory effect on IL-14 and IL-15 production, an inhibitory effect on MMP-1 production, an inhibitory effect on TNFa production, and the like. ing.
- CRAC C inhibitors have an inhibitory effect on cell proliferation, they prevent or treat proliferative or progressive diseases such as malignant tumors, arteriosclerosis, multiple organ sclerosis, various fibrosis and keloids in burns.
- CRAC C inhibitors inhibit the activation of mast cells, inflammatory cells, and cells involved in the inflammatory response in peripheral or central tissues such as astrocytes, resulting in ischemia-reperfusion injury and head trauma. It is also expected to have a protective effect against tissue injuries such as cerebral infarction and myocardial infarction.
- the compound of the present invention which has a CRACC selective inhibitory effect on VOCC, can exhibit a CRACC inhibitory effect without accompanying unfavorable effects in the central nerve or vascular smooth muscle caused by VOCC inhibition. Can be useful.
- a 96-well micro-mouth plate was prepared in which 100 1 of a Jurkat cell (6 ⁇ 10 Vm 1) suspension loaded with the calcium indicator fluorescent dye fura-2 (1 M) was dispensed into each well.
- Calcium pump inhibitor (subcigargin) Stimulation Increased intracellular calcium concentration is caused by adding twice the final concentration of the test drug and Hanks' balanced salt solution 100 1 containing 2 M sapshigargin (final concentration, 1 ⁇ M) to each well.
- the fluorescence intensity ratio (R) was calculated from the two fluorescence intensities obtained at an excitation wavelength of 340 nm / 500 nm and an excitation wavelength of 380 nm / 500 nm.
- the autofluorescence of the test drug itself was measured in the same manner using a cell-free system in advance, and the effect of autofluorescence on fura-2 fluorescence was corrected.
- the intracellular calcium concentration was 25, the maximum response fluorescence intensity ratio (Rmax) obtained by stimulating ionomycin, 5; the minimum response fluorescence intensity ratio (Rmin) obtained by stimulating thionomycin + ImM EGTA, at an excitation wavelength of 380 nm.
- PC 12-h5 loaded with calcium indicator fluorescent dye fura-2 (1 M) Prepare a 96-well microplate in which 100 1 suspension of rat neuroblasts (2 x 10 6 Zm 1) 100 is dispensed into each well did.
- High calcium chloride-stimulated intracellular calcium concentration can be increased by adding a test drug at twice the final concentration and a Hanks balanced salt solution 10 1 containing 10 OmM KC 1 (final concentration, 5 OmM) to each well.
- the fluorescence intensity ratio (R) was calculated from the two fluorescence intensities obtained at excitation wavelengths of 340 nm / 500 nm and 380 nm / 500 nm.
- the autofluorescence intensity ratio the autofluorescence of the test drug itself was measured in the same way using a cell-free system in advance, and the effect of autofluorescence on fura-2 fluorescence was corrected.
- the IC5 () value of the VOCC inhibitory action was calculated and compared in the same manner as the CRACC inhibitory action.
- Example 1 5, 32, 36, 38, 50, 53 and the novel compounds of 72, CRACC inhibitory activity of a known compound of parallel compounds beauty A and Compound D (purchased from both MYBR I DGE Inc.) (IC 5. Value ) Ranged from 0.51 to 0.050 xM. In addition, CRACC inhibitory activity of these compounds It was 16 to 200 or more better than the activity, and had selectivity.
- IL-2 production inhibitory activity was tested according to the method described in S. Clare Chung et al., Br. J. Pharmacol., 113: 861-868 (1994), and its IC 5 was determined . The value was determined.
- IC 50 values of Examples 1, 5, 32, 36, 38, 50, 53 and 72, and Compounds A and D were 1 or less.
- a pharmaceutical composition comprising the compound of the present invention ( ⁇ ) or a salt thereof and a pharmaceutically acceptable carrier comprises one or more of the compound represented by the general formula ( ⁇ ) or a salt thereof, It can be prepared by a commonly used method using pharmaceutical carriers, excipients, and other additives usually used for formulation.
- the drug can be administered orally in the form of tablets, pills, capsules, granules, powders, liquids, etc., or parenteral injections such as intravenous injections, intramuscular injections, suppositories, transdermals, etc. You may.
- the one or more active substances comprise at least one inert diluent, such as sugar, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyridone, metasilicate. It is mixed with magnesium aluminate.
- the composition may be formulated in a conventional manner with additives other than inert diluents, such as lubricants such as magnesium stearate, disintegrants such as calcium cellulose glycolate, stabilizers such as lactose, A solubilizing agent such as glutamic acid or aspartic acid may be contained.
- tablets or pills may be coated with a sugar coating such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose or the like, or with a film of a gastric or enteric substance.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsifiers, solutions, suspensions, syrups, elixirs, etc. and include commonly used inert diluents, eg, purified. Contains water and ethanol. The composition may contain, in addition to the inert diluent, adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, flavoring agents, and preservatives. Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of 7-solution solutions and suspensions include distilled water for injection and Physiological saline solution is included.
- water-insoluble solutions and suspensions examples include propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as ethanol, and polysorbate 80.
- Such compositions may also contain adjuvants such as preserving, wetting, emulsifying, dispersing, and stabilizing agents (eg, lactose) and solubilizing agents (eg, glutamic acid, aspartic acid). But you can. These are sterilized by, for example, filtration through a bacteria retaining filter, blending of a bactericide or irradiation. They can also be used in the manufacture of sterile solid compositions which are dissolved in sterile water or sterile injectable solvents before use.
- the daily dose is about 0.001 to 1 Omg Zkg per body weight, which is administered once or in 2 to 4 doses.
- the daily dose is preferably about 0.001 to 1111 1 g per body weight, administered every few days or once a day or divided into several parts. The dose is determined as appropriate for each individual case, taking into account symptoms, age, sex, and the like.
- Example 1 4-Methylthiazol-5-carboxylic acid (108 mg), 4- [3,5-bis (trifluoromethyl) -1H-pyrazole-1-yl] aniline (223 mg), WSCD hydrochloride (152 mg) and A mixture of DCE (5 ml) was stirred at room temperature overnight. Water (10 ml) was added to the reaction solution, and the product was extracted with a mixed solvent of getyl ether (5 ml) and ethyl acetate (10 ml). The extract was washed sequentially with 1N hydrochloric acid, a saturated aqueous solution of sodium hydrogencarbonate, and saturated saline. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure.
- 4-Methyl-4 '-[3,5-bis (trifluoromethyl) -1H-pyrazole-l-yl] thiazo-l-u-5-potoxylnylide (143 mg) was obtained as colorless needles.
- Example 3 In the silica gel column chromatography treatment of Example 3, the compound eluted after the compound of Example 3 was recrystallized from a mixed solvent of ethyl acetate and hexane to give 4′-chloro-5— (1,4— Dimethyl-3-trifluoromethyl-1H-pyrazole-5-yl) thiophene-2-carboxyanilide (86 mg) was obtained as colorless powdery crystals.
- a mixture of this and methylhydrazine (0.122 ml), acetic acid (lm1) and ethanol (10 ml) was stirred for 15 hours under heating and reflux. After allowing the reaction solution to cool, it was concentrated under reduced pressure. Ethyl acetate was added to the obtained residue, and the mixture was washed successively with a saturated aqueous solution of sodium hydrogen carbonate and a saturated saline solution. The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure.
- Example 9 In the silica gel column chromatography treatment of Example 9, the compound eluted after the compound of Example 9 was recrystallized from a mixed solvent of ethyl acetate and hexane to give 4-chloro-3,1- (1-methyl-3-) Trifluoromethyl-1H-pyrazole-5-yl) benzanilide (134 mg) was obtained as colorless powdery crystals.
- Ethyl 1- [4- (4-chlorobenzoylamino) phenyl] -15-trifluoromethyl-1H_pyrazolulu 4-carboxylate (15 Omg), 1N aqueous sodium hydroxide solution (1ml), and ethanol (2ml) was stirred at 4 for 4 hours. After cooling, a 1N aqueous hydrochloric acid solution (2 ml) was added to the reaction solution, and the product was extracted with ethyl acetate. The extract was washed with saturated saline. The organic layer was dried over anhydrous magnesium sulfate and concentrated under reduced pressure.
- Example 16 4- (1-Methyl-3-trifluoromethyl-1H-pyrazole_5-yl) To a mixture of piperidine (540 mg) and THF (5 ml) under ice-cooling, (461 mg) and the mixture was stirred at room temperature overnight. Water (10 ml) was added to the reaction solution, the product was extracted with ethyl acetate, and the extract was washed with saturated saline. The organic layer was dried over anhydrous magnesium sulfate and then concentrated under reduced pressure. A mixed solvent of acetone and diethyl ether was added to the obtained residue, the insolubles were removed by filtration, and the filtrate was concentrated under reduced pressure.
- the reaction solution was concentrated under reduced pressure, ethyl ether was added to the obtained residue, and the mixture was concentrated under reduced pressure.
- a mixed solvent of ethanol and getyl ether was added to the obtained residue, the insoluble material was removed by filtration, and the filtrate was concentrated under reduced pressure.
- Table 1 shows the structural formula and physicochemical properties of the reference compound
- Tables 2 and 3 show the structural formula and physicochemical properties of the example compound.
- the compounds whose chemical structural formulas are listed in Tables 4 and 5 are almost the same as the methods described in the above Examples and Production Methods, or by applying slight variations obvious to those skilled in the art. And easily manufactured.
Description
Claims
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/529,131 US6348480B1 (en) | 1997-10-13 | 1998-10-12 | Pharmaceutical compound comprising a pyrazole derivative and methods of using the same for the treatment of calcium release-activated calcium channel associated diseases |
EP98947818A EP1024138B1 (en) | 1997-10-13 | 1998-10-12 | Pyrazole derivatives |
AU94593/98A AU9459398A (en) | 1997-10-13 | 1998-10-12 | Pyrazole derivatives |
CA002304979A CA2304979A1 (en) | 1997-10-13 | 1998-10-12 | Pyrazole derivatives having a calcium release-activated calcium channel inhibitory effect |
DE69837675T DE69837675T2 (de) | 1997-10-13 | 1998-10-12 | Pyrazolderivate |
NO20001907A NO317417B1 (no) | 1997-10-13 | 2000-04-12 | Pyrazolderivater |
US09/773,736 US6958339B2 (en) | 1997-10-13 | 2001-02-02 | Pyrazole derivative |
US11/154,591 US7247635B2 (en) | 1997-10-13 | 2005-06-17 | Pyrazole derivative |
US11/399,379 US7285554B2 (en) | 1997-10-13 | 2006-04-07 | Pyrazole derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP9/279093 | 1997-10-13 | ||
JP27909397 | 1997-10-13 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09529131 A-371-Of-International | 1998-10-12 | ||
US09/773,736 Division US6958339B2 (en) | 1997-10-13 | 2001-02-02 | Pyrazole derivative |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999019303A1 true WO1999019303A1 (fr) | 1999-04-22 |
Family
ID=17606326
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/004583 WO1999019303A1 (fr) | 1997-10-13 | 1998-10-12 | Derives de pyrazole |
Country Status (18)
Country | Link |
---|---|
US (4) | US6348480B1 (ja) |
EP (1) | EP1024138B1 (ja) |
KR (1) | KR100589868B1 (ja) |
CN (1) | CN1107671C (ja) |
AR (1) | AR016957A1 (ja) |
AT (1) | ATE360618T1 (ja) |
AU (2) | AU751139B2 (ja) |
BR (1) | BR9803883A (ja) |
CA (1) | CA2304979A1 (ja) |
DE (1) | DE69837675T2 (ja) |
ES (1) | ES2285784T3 (ja) |
HU (1) | HUP9802310A1 (ja) |
NO (1) | NO317417B1 (ja) |
PL (1) | PL192411B1 (ja) |
PT (1) | PT1024138E (ja) |
RU (1) | RU2185381C2 (ja) |
TW (1) | TW495498B (ja) |
WO (1) | WO1999019303A1 (ja) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051580A1 (en) * | 1998-04-08 | 1999-10-14 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
WO1999062885A1 (en) * | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
WO2000006153A1 (en) * | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Propenamides as ccr5 modulators |
WO2001072740A1 (en) * | 2000-03-23 | 2001-10-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl) triazoles and their use as anti-inflammatory agents |
US6794397B2 (en) * | 2000-01-27 | 2004-09-21 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
JP2005530748A (ja) * | 2002-04-27 | 2005-10-13 | アストラゼネカ アクチボラグ | ヒストンデアセチラーゼ阻害剤 |
WO2006054652A1 (ja) * | 2004-11-18 | 2006-05-26 | Takeda Pharmaceutical Company Limited | アミド化合物 |
JP2007530594A (ja) * | 2004-03-25 | 2007-11-01 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫に関連する用途に用いられるアクリロニトリル誘導体 |
US7309710B2 (en) | 2002-08-27 | 2007-12-18 | Astellas Pharma Inc. | Crystals |
JP2010501567A (ja) * | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−CoA不飽和化酵素(SCD)阻害剤としての2−(ピラジン−2−イル)−チアゾールおよび2−(1H−ピラゾール−3−イル)チアゾール誘導体ならびに関連化合物 |
WO2010126002A1 (ja) * | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
CN105503832A (zh) * | 2015-12-18 | 2016-04-20 | 浙江大学 | 取代吡唑环类衍生物及其用途 |
JP2016540823A (ja) * | 2013-12-19 | 2016-12-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | フルオロ置換ピロールカルボキサミドiv |
JP2016540821A (ja) * | 2013-12-19 | 2016-12-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | フルオロメチル置換ピロールカルボキサミドiii |
US10646582B2 (en) | 2013-07-30 | 2020-05-12 | Genevant Sciences Gmbh | Block copolymers |
US11219634B2 (en) | 2015-01-21 | 2022-01-11 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
US11684584B2 (en) | 2016-12-30 | 2023-06-27 | Genevant Sciences Gmbh | Branched peg molecules and related compositions and methods |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU751139B2 (en) * | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
WO2000006550A1 (fr) * | 1998-07-31 | 2000-02-10 | Nippon Soda Co., Ltd. | Composes phenylazole, procede de production desdits composes et medicaments pour le traitement de l'hyperlipidemie |
JP2001031509A (ja) * | 1999-07-15 | 2001-02-06 | Nippon Bayer Agrochem Co Ltd | チエニル−ピラゾール類の有害生物防除剤としての利用 |
US6353007B1 (en) * | 2000-07-13 | 2002-03-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)indoles and their use as anti-inflammatory agents |
EP1186661A1 (en) * | 2000-09-05 | 2002-03-13 | Warner-Lambert Company | Identification of the major capacitative calcium channel in antigen presenting cells and uses thereof |
EP1184457A1 (en) * | 2000-09-05 | 2002-03-06 | Warner-Lambert Company | Identification of a capacitative calcium channel in antigen presenting cells and uses thereof |
KR20030064852A (ko) | 2000-12-22 | 2003-08-02 | 이시하라 산교 가부시끼가이샤 | 아닐린 유도체 또는 그의 염 및 이들을 함유하는사이토카인 생산 억제제 |
EP1401427A4 (en) * | 2001-06-06 | 2004-12-01 | Agouron Pharma | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOF, PROCESSES FOR THE PREPARATION THEREOF |
MXPA03011681A (es) * | 2001-06-29 | 2004-03-19 | Boehringer Ingelheim Pharma | Uso de inhibidores de epoxido hidrolasa soluble, para tratar enfermedades relacionadas con la enfermedad cardiovascular. |
WO2004035566A1 (en) * | 2002-10-18 | 2004-04-29 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7790724B2 (en) * | 2003-04-25 | 2010-09-07 | Janssen Pharmaceutica N.V. | c-fms kinase inhibitors |
AU2004259347B2 (en) * | 2003-07-23 | 2011-02-24 | Synta Pharmaceuticals, Corp. | Method for modulating calcium ion-release-activated calcium ion channels |
EP1706385B1 (en) | 2003-12-23 | 2010-10-06 | Astex Therapeutics Limited | Pyrazole derivatives as protein kinase modulators |
DE602005014621D1 (de) * | 2004-03-09 | 2009-07-09 | Boehringer Ingelheim Pharma | 3-ä4-heterocyclyl-1,2,3-triazol-1-ylü-n-arylbenzamide als inhibitoren der cytokinenproduktion für die behandlung von chronischen entzündlichen erkrankungen |
CA2606239A1 (en) * | 2005-04-22 | 2006-11-02 | Astellas Pharma Inc. | Preventive or remedy for bowel disease |
GB2427406A (en) * | 2005-06-21 | 2006-12-27 | Astex Technology Ltd | Silicon-containing PKB/PKA kinase inhibitors |
WO2006136821A1 (en) | 2005-06-22 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical compounds |
WO2006136837A2 (en) | 2005-06-23 | 2006-12-28 | Astex Therapeutics Limited | Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators |
EP1984337B1 (en) * | 2006-01-25 | 2014-04-30 | Synta Pharmaceuticals Corp. | Vinyl-phenyl derivatives for inflammation and immune-related uses |
AU2013200480B2 (en) * | 2006-02-28 | 2016-06-09 | Dart Neuroscience (Cayman) Ltd. | Therapeutic compounds |
AU2007221021B2 (en) | 2006-02-28 | 2013-01-17 | Dart Neuroscience (Cayman) Ltd | Therapeutic piperazines as PDE4 inhibitors |
WO2007100851A1 (en) | 2006-02-28 | 2007-09-07 | Helicon Therapeutics, Inc. | Therapeutic compounds |
US7803799B2 (en) * | 2006-07-07 | 2010-09-28 | National Health Research Institutes | Selenophene compounds |
EP2058309A4 (en) * | 2006-08-04 | 2010-12-22 | Takeda Pharmaceutical | CONDENSED HETEROCYCLIC COMPOUND |
JP5336375B2 (ja) | 2006-08-30 | 2013-11-06 | セルゾーム リミテッド | キナーゼ阻害剤としてのトリアゾール誘導体 |
TWI339205B (en) * | 2006-10-02 | 2011-03-21 | Nat Health Research Institutes | Pyrazole compounds and pharmaceutical composition |
TWI408136B (zh) * | 2006-10-02 | 2013-09-11 | Nat Health Research Institutes | 噻吩化合物及其醫藥組成物 |
UY30892A1 (es) * | 2007-02-07 | 2008-09-02 | Smithkline Beckman Corp | Inhibidores de la actividad akt |
AU2008222602B2 (en) | 2007-03-05 | 2013-06-20 | The University Of Queensland | A target for breast cancer therapy and/or diagnosis |
GB0704932D0 (en) | 2007-03-14 | 2007-04-25 | Astex Therapeutics Ltd | Pharmaceutical compounds |
ES2748599T3 (es) | 2007-08-27 | 2020-03-17 | Dart Neuroscience Cayman Ltd | Compuestos terapéuticos de isoxazol |
GB0801888D0 (en) * | 2008-02-01 | 2008-03-12 | Isis Innovation | Treatment of mast cell related disorders |
DE102008014523A1 (de) * | 2008-03-15 | 2009-09-17 | Robert Bosch Gmbh | Heizgerät |
US8598355B2 (en) | 2008-05-14 | 2013-12-03 | Astellas Pharma Inc. | Amide compound |
JP2010030970A (ja) * | 2008-07-31 | 2010-02-12 | Bayer Cropscience Ag | 殺虫性ベンゼンジカルボキサミド誘導体 |
TWI434686B (zh) * | 2008-11-03 | 2014-04-21 | Nat Health Research Institutes | 咪唑-4-酮及咪唑-4-硫酮化合物 |
UY32407A (es) * | 2009-01-30 | 2010-07-30 | Glaxosmithkline Llc | Hidrocloruro de n-{(1s)-2-amino-1-[(3-fluorofenil)metil]etil}-5-cloro-4-(4-cloro-1-metil-1h-pirazol-5-il)-2-tiofenocarboxamida cristalino |
TW201103892A (en) * | 2009-04-24 | 2011-02-01 | Glaxo Group Ltd | Compounds |
EP2421834A1 (en) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Pyrazole and triazole carboxamides as crac channel inhibitors |
WO2010144664A1 (en) * | 2009-06-12 | 2010-12-16 | Schering Corporation | Thiophenes as glucagon receptor antagonists, compositions, and methods for their use |
US8377970B2 (en) | 2009-10-08 | 2013-02-19 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel |
US8993612B2 (en) * | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
AU2011248877B9 (en) | 2010-04-27 | 2015-11-05 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
CA2797533A1 (en) | 2010-04-27 | 2011-11-10 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
AU2011293201B2 (en) | 2010-08-27 | 2015-11-05 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
WO2012052458A1 (en) | 2010-10-21 | 2012-04-26 | Glaxo Group Limited | Pyrazole compounds acting against allergic, immune and inflammatory conditions |
US9149462B2 (en) | 2010-10-21 | 2015-10-06 | Glaxo Group Limited | Pyrazole compounds acting against allergic, inflammatory and immune disorders |
CA2834928C (en) * | 2011-05-03 | 2017-10-17 | Synta Pharmaceuticals Corp. | Compounds for inflammation and immune-related uses |
WO2012170931A2 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US20140256771A1 (en) * | 2011-10-19 | 2014-09-11 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
US9856240B2 (en) | 2011-10-19 | 2018-01-02 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
IN2014MN02127A (ja) | 2012-05-02 | 2015-09-11 | Lupin Ltd | |
US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
AU2014204978A1 (en) | 2013-01-10 | 2015-08-20 | Grünenthal GmbH | Pyrazolyl-based carboxamides I as CRAC channel inhibitors |
EP2943197A1 (en) | 2013-01-10 | 2015-11-18 | Grünenthal GmbH | Pyrazolyl-based carboxamides ii as crac channel inhibitors |
CN104926801B (zh) * | 2014-03-22 | 2019-06-04 | 浙江大学 | 取代氮杂环类衍生物、含其的药物组合物及其在抗肿瘤中的应用 |
WO2015197187A1 (en) | 2014-06-24 | 2015-12-30 | Grünenthal GmbH | Pyrazolyl-based carboxamides v |
AR103807A1 (es) | 2015-02-27 | 2017-06-07 | Calcimedica Inc | Tratamiento de la pancreatitis |
WO2017027400A1 (en) | 2015-08-07 | 2017-02-16 | Calcimedica, Inc. | Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury |
BR112021004893A2 (pt) | 2018-09-14 | 2021-06-01 | Rhizen Pharmaceuticals A G | composições compreendendo um inibidor de crac e um corticosteroide e métodos de uso dos mesmos |
CN111187204B (zh) * | 2020-01-13 | 2022-11-08 | 海利尔药业集团股份有限公司 | 一种啶虫脒共晶及其制备方法、用途 |
WO2021174174A1 (en) * | 2020-02-28 | 2021-09-02 | Remix Therapeutics Inc. | Thiophenyl derivatives useful for modulating nucleic acid splicing |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01287071A (ja) * | 1988-01-07 | 1989-11-17 | E I Du Pont De Nemours & Co | 置換されたピロール、ピラゾールおよびトリアゾールアンジオテンシン2アンタゴニスト |
JPH03141261A (ja) * | 1989-09-22 | 1991-06-17 | Fujisawa Pharmaceut Co Ltd | ピラゾール誘導体、その製造法およびそれを含有する医薬組成物 |
JPH04234851A (ja) * | 1990-03-19 | 1992-08-24 | Lab Up Sa | アンギオテンシンii受容体アンタゴニストである新規ピラゾール誘導体およびその製造方法とそれを含む薬物組成物 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3401911A1 (de) * | 1984-01-20 | 1985-08-01 | A. Nattermann & Cie GmbH, 5000 Köln | Substituierte 4,5-dihydro-6-vinyl-3(2h)-pyridazinone und 6-vinyl-3(2h)-pyridazinone sowie verfahren zu ihrer herstellung |
GB8409986D0 (en) * | 1984-04-17 | 1984-05-31 | Beecham Group Plc | Beta-lactam antibacterial agents |
GR851296B (ja) * | 1984-05-29 | 1985-11-25 | Pfizer | |
JPS6455557A (en) * | 1987-08-26 | 1989-03-02 | Fuji Photo Film Co Ltd | Silver halide color photographic sensitive material |
US5571821A (en) * | 1993-05-20 | 1996-11-05 | Texas Biotechnology Corporation | Sulfonamides and derivatives thereof that modulate the activity of endothelin |
JPH0419721Y2 (ja) | 1987-09-29 | 1992-05-06 | ||
JP2867450B2 (ja) | 1989-08-17 | 1999-03-08 | 吉富製薬株式会社 | アルキレンビスアミド化合物 |
DE4126994A1 (de) * | 1991-08-16 | 1993-02-18 | Basf Ag | (alpha)-arylacrylsaeurederivate, ihre herstellung und verwendung zur bekaempfung von schaedlingen und pilzen |
JP3141261B2 (ja) | 1992-10-22 | 2001-03-05 | 松下電工株式会社 | 警報表示器 |
US5739135A (en) | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
JPH07225401A (ja) * | 1994-02-14 | 1995-08-22 | Fuji Photo Film Co Ltd | 非線形光学材料 |
KR970706242A (ko) * | 1994-10-04 | 1997-11-03 | 후지야마 아키라 | 우레아 유도체 및 ACAT-억제제로서 그의 용도(Urea derivatives and their use as ACAT-inhibitors) |
TR199700749T1 (xx) * | 1995-02-02 | 1998-02-21 | Smithkline Beecham P.L.C. | 5-HT resept�r antagonisti olarak indole t�revleri. |
AU5426296A (en) * | 1995-04-04 | 1996-10-23 | E.I. Du Pont De Nemours And Company | Herbicidal heteroaryl-substituted anilides |
JPH10507205A (ja) | 1995-08-02 | 1998-07-14 | ホータ.ウリアッヒ イ シイア.エセ.アー. | 抗真菌活性を有する新規カルボンアミド |
JPH1072434A (ja) * | 1996-04-08 | 1998-03-17 | Nissan Chem Ind Ltd | 2,4−置換アニリン誘導体 |
AU6229298A (en) | 1997-02-20 | 1998-09-09 | Shionogi & Co., Ltd. | Indole dicarboxylic acid derivatives |
AU6320998A (en) * | 1997-02-21 | 1998-09-09 | Bristol-Myers Squibb Company | Benzoic acid derivatives and related compounds as antiarrhythmic agents |
DE19708928A1 (de) * | 1997-03-05 | 1998-09-10 | Bayer Ag | Substituierte aromatische Aminoverbindungen |
DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
AU751139B2 (en) * | 1997-10-13 | 2002-08-08 | Astellas Pharma Inc. | Amide derivative |
JP2002510679A (ja) * | 1998-04-08 | 2002-04-09 | アボット・ラボラトリーズ | ピラゾールサイトカイン産生阻害剤 |
CA2332957A1 (en) * | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
US6140509A (en) * | 1998-06-26 | 2000-10-31 | Arena Pharmaceuticals, Inc. | Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof |
US20010044445A1 (en) | 1999-04-08 | 2001-11-22 | Bamaung Nwe Y. | Azole inhibitors of cytokine production |
-
1998
- 1998-09-29 AU AU87139/98A patent/AU751139B2/en not_active Ceased
- 1998-10-06 BR BR9803883-4A patent/BR9803883A/pt not_active IP Right Cessation
- 1998-10-09 RU RU98118557/04A patent/RU2185381C2/ru not_active IP Right Cessation
- 1998-10-12 EP EP98947818A patent/EP1024138B1/en not_active Expired - Lifetime
- 1998-10-12 CA CA002304979A patent/CA2304979A1/en not_active Abandoned
- 1998-10-12 AT AT98947818T patent/ATE360618T1/de not_active IP Right Cessation
- 1998-10-12 HU HU9802310A patent/HUP9802310A1/hu unknown
- 1998-10-12 US US09/529,131 patent/US6348480B1/en not_active Expired - Fee Related
- 1998-10-12 KR KR1019980042475A patent/KR100589868B1/ko not_active IP Right Cessation
- 1998-10-12 WO PCT/JP1998/004583 patent/WO1999019303A1/ja active IP Right Grant
- 1998-10-12 AU AU94593/98A patent/AU9459398A/en not_active Abandoned
- 1998-10-12 TW TW087116918A patent/TW495498B/zh not_active IP Right Cessation
- 1998-10-12 ES ES98947818T patent/ES2285784T3/es not_active Expired - Lifetime
- 1998-10-12 PL PL329150A patent/PL192411B1/pl not_active IP Right Cessation
- 1998-10-12 DE DE69837675T patent/DE69837675T2/de not_active Expired - Fee Related
- 1998-10-12 PT PT98947818T patent/PT1024138E/pt unknown
- 1998-10-13 AR ARP980105064A patent/AR016957A1/es unknown
- 1998-10-13 CN CN98121354A patent/CN1107671C/zh not_active Expired - Fee Related
-
2000
- 2000-04-12 NO NO20001907A patent/NO317417B1/no not_active IP Right Cessation
-
2001
- 2001-02-02 US US09/773,736 patent/US6958339B2/en not_active Expired - Fee Related
-
2005
- 2005-06-17 US US11/154,591 patent/US7247635B2/en not_active Expired - Fee Related
-
2006
- 2006-04-07 US US11/399,379 patent/US7285554B2/en not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01287071A (ja) * | 1988-01-07 | 1989-11-17 | E I Du Pont De Nemours & Co | 置換されたピロール、ピラゾールおよびトリアゾールアンジオテンシン2アンタゴニスト |
JPH03141261A (ja) * | 1989-09-22 | 1991-06-17 | Fujisawa Pharmaceut Co Ltd | ピラゾール誘導体、その製造法およびそれを含有する医薬組成物 |
JPH04234851A (ja) * | 1990-03-19 | 1992-08-24 | Lab Up Sa | アンギオテンシンii受容体アンタゴニストである新規ピラゾール誘導体およびその製造方法とそれを含む薬物組成物 |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999051580A1 (en) * | 1998-04-08 | 1999-10-14 | Abbott Laboratories | Pyrazole inhibitors of cytokine production |
WO1999062885A1 (en) * | 1998-06-05 | 1999-12-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
US6506747B1 (en) * | 1998-06-05 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents |
WO2000006153A1 (en) * | 1998-07-28 | 2000-02-10 | Smithkline Beecham Corporation | Propenamides as ccr5 modulators |
US6794397B2 (en) * | 2000-01-27 | 2004-09-21 | Cytovia, Inc. | Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof |
WO2001072740A1 (en) * | 2000-03-23 | 2001-10-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenyl) triazoles and their use as anti-inflammatory agents |
US6451820B1 (en) | 2000-03-23 | 2002-09-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted 1-(4-aminophenly)triazoles and their use as anti-inflammatory agents |
JP2005530748A (ja) * | 2002-04-27 | 2005-10-13 | アストラゼネカ アクチボラグ | ヒストンデアセチラーゼ阻害剤 |
US7309710B2 (en) | 2002-08-27 | 2007-12-18 | Astellas Pharma Inc. | Crystals |
JP2007530594A (ja) * | 2004-03-25 | 2007-11-01 | シンタ ファーマシューティカルズ コーポレーション | 炎症及び免疫に関連する用途に用いられるアクリロニトリル誘導体 |
WO2006054652A1 (ja) * | 2004-11-18 | 2006-05-26 | Takeda Pharmaceutical Company Limited | アミド化合物 |
US7851473B2 (en) | 2004-11-18 | 2010-12-14 | Takeda Pharmaceutical Company Limited | Amide compound |
JP2010501567A (ja) * | 2006-08-24 | 2010-01-21 | ノバルティス アクチエンゲゼルシャフト | 代謝系、心血管系および他の障害の処置のためのステアロイル−CoA不飽和化酵素(SCD)阻害剤としての2−(ピラジン−2−イル)−チアゾールおよび2−(1H−ピラゾール−3−イル)チアゾール誘導体ならびに関連化合物 |
WO2010126002A1 (ja) * | 2009-04-28 | 2010-11-04 | 塩野義製薬株式会社 | ヘテロ環スルホンアミド化合物を含有する医薬 |
US10646582B2 (en) | 2013-07-30 | 2020-05-12 | Genevant Sciences Gmbh | Block copolymers |
US11938191B2 (en) | 2013-07-30 | 2024-03-26 | Genevant Sciences Gmbh | Block copolymers |
JP2016540823A (ja) * | 2013-12-19 | 2016-12-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | フルオロ置換ピロールカルボキサミドiv |
JP2016540821A (ja) * | 2013-12-19 | 2016-12-28 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | フルオロメチル置換ピロールカルボキサミドiii |
US11219634B2 (en) | 2015-01-21 | 2022-01-11 | Genevant Sciences Gmbh | Methods, compositions, and systems for delivering therapeutic and diagnostic agents into cells |
CN105503832A (zh) * | 2015-12-18 | 2016-04-20 | 浙江大学 | 取代吡唑环类衍生物及其用途 |
US11684584B2 (en) | 2016-12-30 | 2023-06-27 | Genevant Sciences Gmbh | Branched peg molecules and related compositions and methods |
Also Published As
Publication number | Publication date |
---|---|
NO317417B1 (no) | 2004-10-25 |
AU751139B2 (en) | 2002-08-08 |
US6348480B1 (en) | 2002-02-19 |
EP1024138A4 (en) | 2002-02-06 |
US7285554B2 (en) | 2007-10-23 |
CA2304979A1 (en) | 1999-04-22 |
ATE360618T1 (de) | 2007-05-15 |
PL192411B1 (pl) | 2006-10-31 |
BR9803883A (pt) | 2000-05-16 |
KR19990037018A (ko) | 1999-05-25 |
AU9459398A (en) | 1999-05-03 |
US20060264430A1 (en) | 2006-11-23 |
KR100589868B1 (ko) | 2006-10-24 |
PL329150A1 (en) | 1999-04-26 |
DE69837675D1 (en) | 2007-06-06 |
US7247635B2 (en) | 2007-07-24 |
NO20001907D0 (no) | 2000-04-12 |
HU9802310D0 (en) | 1998-12-28 |
AR016957A1 (es) | 2001-08-01 |
US6958339B2 (en) | 2005-10-25 |
CN1218046A (zh) | 1999-06-02 |
HUP9802310A1 (hu) | 2000-03-28 |
EP1024138B1 (en) | 2007-04-25 |
PT1024138E (pt) | 2007-08-01 |
TW495498B (en) | 2002-07-21 |
NO20001907L (no) | 2000-06-09 |
AU8713998A (en) | 1999-04-29 |
US20050234055A1 (en) | 2005-10-20 |
CN1107671C (zh) | 2003-05-07 |
DE69837675T2 (de) | 2008-01-10 |
RU2185381C2 (ru) | 2002-07-20 |
US20010011090A1 (en) | 2001-08-02 |
EP1024138A1 (en) | 2000-08-02 |
ES2285784T3 (es) | 2007-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999019303A1 (fr) | Derives de pyrazole | |
KR101804588B1 (ko) | 조혈 성장 인자 모방체 소분자 화합물 및 이의 용도 | |
JP4120586B2 (ja) | 2−アシルアミノチアゾール誘導体又はその塩 | |
JP5408434B2 (ja) | アミド化合物 | |
JP5517935B2 (ja) | 細胞壊死阻害剤としてのインドール及びインダゾール化合物 | |
CN101636397A (zh) | 脲类化合物、其制备方法及其医药用途 | |
CA2829790A1 (en) | Multisubstituted aromatic compounds as inhibitors of thrombin | |
JP2000256358A (ja) | ピラゾール誘導体 | |
JP2001526220A (ja) | 置換複素環式尿素を用いたrafキナーゼの阻害 | |
JP2003511414A (ja) | FabI阻害剤 | |
AU714701B2 (en) | Novel thiophene derivative and pharmaceutical composition thereof | |
JP4385414B2 (ja) | アミド若しくはアミン誘導体 | |
JP2021515787A (ja) | アミノ−ベンゾイソチアゾール及びアミノ−ベンゾイソチアジアゾールのアミド化合物 | |
AU2004228119B2 (en) | Pyrazole compounds | |
JP2003510323A (ja) | 医薬として活性なスルホニル・ヒドラジド誘導体 | |
WO2012038904A1 (fr) | Derives de nicotinamide, leur preparation et leur application en therapeutique | |
AU2001287990B2 (en) | Pharmaceutically active hydrophilic sulfonamide derivatives as inhibitors of protein junkinases | |
JP2005513018A (ja) | Alk5阻害剤としてのチアゾリル置換トリアゾール類 | |
JP2006522039A (ja) | 置換ピラゾール化合物 | |
KR100248643B1 (ko) | 아릴 및 헤테로아릴 알콕시나프탈렌 유도체 | |
CA3162388A1 (en) | 4-phenyl-n-(phenyl)thiazol-2-amine derivatives and related compounds as aryl hydrocarbon receptor (ahr) agonists for the treatment of e.g. angiogenesis implicated or inflammatory disorder | |
JP2001519826A (ja) | 金属プロテイナーゼ阻害剤 | |
CN113980001B (zh) | 吡唑醇-哒嗪酮类耦联化合物、其药物组合物及其在药物中的应用 | |
JP2023134657A (ja) | 新規抗腫瘍剤 | |
MXPA98008433A (en) | Derivatives of amida and pharmaceutical composition that contains them, useful as caliber channel inhibitor activated by the release of cal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GD GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1998947818 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2304979 Country of ref document: CA Ref country code: CA Ref document number: 2304979 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09529131 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1998947818 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 2000515876 Format of ref document f/p: F |
|
WWG | Wipo information: grant in national office |
Ref document number: 1998947818 Country of ref document: EP |